<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.6//EN"
"http://www.ncbi.nlm.nih.gov/corehtml/query/static/PubMed.dtd">
<ArticleSet>
     <Article>
        <Journal>
            <PublisherName>Nature Publishing Group</PublisherName>
            <JournalTitle>Nature Chemical Biology</JournalTitle>
            <Issn>1552-4450</Issn>
            <Volume>4</Volume>
            <Issue>2</Issue>
            <PubDate PubStatus="ppublish">
                <Year>2008</Year>
                <Month>February</Month>
            </PubDate>
        </Journal>
        <ArticleTitle>High-content single-cell drug screening with
phosphospecific flow cytometry</ArticleTitle>
        <FirstPage>132</FirstPage>
        <LastPage>142</LastPage> 
  <ELocationID EIdType="pii">nchembio.2007.59</ELocationID> 
  <ELocationID EIdType="doi">10.1038/nchembio.2007.59</ELocationID>
        <Language>EN</Language>
        <AuthorList>
            <Author>
                <FirstName>Peter</FirstName> 
                <MiddleName>O</MiddleName>
                <LastName>Krutzik</LastName> 
          <Suffix>Jr</Suffix>
                <Affiliation>
Department of Microbiology and Immunology,
Baxter Laboratory in Genetic Pharmacology, Stanford University, 
269 Campus Drive, Stanford, California 94305, USA. 
                </Affiliation>
            </Author>
            <Author>
                <FirstName>Janelle M</FirstName>
                <LastName>Crane</LastName>
            </Author>
            <Author>
                <CollectiveName>Cancer Genome Project</CollectiveName>
            </Author>            
            <Author>
                <FirstName>Matthew R</FirstName>
                <LastName>Clutter</LastName>
            </Author>
            <Author>
                <FirstName>Garry P</FirstName>
                <LastName>Nolan</LastName>
            </Author>
            <Author>
                <CollectiveName>North American Barley
Genome Project</CollectiveName>
            </Author>            
        </AuthorList>
        <GroupList>
           <Group>
              <GroupName>Cancer Genome Project</GroupName>
                 <IndividualName>
                    <FirstName>John</FirstName>
                    <LastName>Smith</LastName>
                 </IndividualName>
                 <IndividualName>
                    <FirstName>Jane</FirstName>
                    <LastName>Smith</LastName>
                 </IndividualName>
        </Group>
           <Group>
              <GroupName>North American Barley Genome Project</GroupName>
                 <IndividualName>
                    <FirstName>John Jacob</FirstName>
                    <LastName>Han</LastName>
                 </IndividualName>
                 <IndividualName>
                    <FirstName>Laura</FirstName>
                    <LastName>Clancy</LastName>
                 </IndividualName>
        </Group>
        </GroupList>
        <ArticleIdList>
            <ArticleId IdType="pii">nchembio.2007.59</ArticleId>
            <ArticleId IdType="doi">10.1038/nchembio.2007.59</ArticleId>
        </ArticleIdList>
        <History>
            <PubDate PubStatus="received">
                <Year>2007</Year>
                <Month>06</Month>
                <Day>15</Day>
            </PubDate>
            <PubDate PubStatus="accepted">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>30</Day>
            </PubDate>
            <PubDate PubStatus="aheadofprint">
                <Year>2007</Year>
                <Month>December</Month>
                <Day>23</Day>
            </PubDate>
        </History>
        <Abstract>
Drug screening is often limited to cell-free assays involving
purified enzymes, but it is arguably best applied against systems
that represent disease states or complex physiological cellular
networks. Here, we describe a high-content, cell-based drug
discovery platform based on phosphospecific flow cytometry, 
or phosphoflow, that enabled screening for inhibitors against
multiple endogenous kinase signaling pathways in heterogeneous
primary cell populations at the single-cell level. From a library
of small-molecule natural products, we identified pathway-selective
inhibitors of Jak-Stat and MAP kinase signaling. Dose-response
experiments in primary cells confirmed pathway selectivity, 
but importantly also revealed differential inhibition of cell
types and new druggability trends across multiple compounds. 
Lead compound selectivity was confirmed in vivo in mice. Phosphoflow
therefore provides a unique platform that can be applied throughout
the drug discovery process, from early compound screening to in
vivo testing and clinical monitoring of drug efficacy.
        </Abstract>
        <ObjectList>
            <Object Type="NCBI:pubchem-substance">
                <Param Name="id">46391334</Param>
            </Object>
            <Object Type="NCBI:pubchem-substance">
                <Param Name="id">46391335</Param>
            </Object>
            <Object Type="NCBI:pubchem-substance">
                <Param Name="id">46391336</Param>
            </Object>
         </ObjectList>
    </Article> 
    <Article>     
        <Journal>
            <PublisherName>Nature Publishing Group</PublisherName>
            <JournalTitle>Nature Chemical Biology</JournalTitle>
            <Issn>1552-4450</Issn>
            <Volume>4</Volume>
            <Issue>2</Issue>
            <PubDate PubStatus="ppublish">
                <Year>2008</Year>
                <Month>February</Month>
            </PubDate>
        </Journal>
        <ArticleTitle>Site selectivity of platinum
anticancer therapeutics</ArticleTitle> 
        <FirstPage>110</FirstPage>
        <LastPage>112</LastPage>
        <Language>EN</Language>
        <AuthorList>
            <Author>
                <FirstName>Bin</FirstName>
                <LastName>Wu</LastName>
                <Affiliation>
Division of Structural and Computational Biology,
School of Biological Sciences, Nanyang Technological University,
60 Nanyang Drive,Singapore 637551, Singapore. 
                </Affiliation>
            </Author>
            <Author>
                <FirstName>Peter</FirstName>
                <LastName>Dr&amp;ouml;ge</LastName>
            </Author>
            <Author>
                <FirstName>Curt A</FirstName>
                <LastName>Davey</LastName>
            </Author>
        </AuthorList>
        <ArticleIdList>
            <ArticleId IdType="pii">nchembio.2007.58</ArticleId>
            <ArticleId IdType="doi">10.1038/nchembio.2007.58</ArticleId>
        </ArticleIdList>
        <History>
            <PubDate PubStatus="received">
                <Year>2007</Year>
                <Month>06</Month>
                <Day>07</Day>
            </PubDate>
            <PubDate PubStatus="accepted">
                <Year>2007</Year>
                <Month>10</Month>
                <Day>26</Day>
            </PubDate>
            <PubDate PubStatus="aheadofprint">
                <Year>2007</Year>
                <Month>December</Month>
                <Day>23</Day>
            </PubDate>
        </History>
        <Abstract>
X-ray crystallographic and biochemical investigation
of the reaction of cisplatin and oxaliplatin with nucleosome core
particle and naked DNA reveals that histone octamer association can
modulate DNA platination. Adduct formation also occurs at specific
histone methionine residues, which could serve as a nuclear platinum
reservoir influencing adduct transfer to DNA. Our findings suggest
that the nucleosome center may provide a favorable target for the
design of improved platinum anticancer drugs. </Abstract>
</Article>
</ArticleSet>
